Skip to main content
Clinical Trials/IRCT20160131026298N3
IRCT20160131026298N3CompletedPhase 2

Evaluation of the effect of Iranian medicine product, Algro, on the symptoms of patients with covid-19 (Coronavirus 19 disease)

Bagheiat-allah University of Medical Sciences0 sites80 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Male or female patients 18 years old and older with COVID-19
  • positive coronavirus 19 PCR
  • Ground glass view at low-dose CT scan
  • Arterial oxygen saturation less than 93%
  • Consciously completed consent form completed by the patient or the patient's supervisor

Exclusion Criteria

  • History of pulmonary malignancy
  • History of asthma or COPD
  • History of Disabling disease or malignancy
  • Liver or kidney disorders

Investigators

Sponsor
Bagheiat-allah University of Medical Sciences

Similar Trials